Guangxin Zhou
oxis@163.com
Chinese, English
Jiangsu
Nanjing University
Medical School
  • Doctor of Medicine
  • Postdoctoral Researcher
  • Recipient of Military Outstanding Scientific Talent Allowance
  • Jiangsu Province '333' High-Level Talent Training Object
  • Jiangsu Province 'Six Talent Peaks' High-Level Talent Training Object
  • Vice Director of Orthopedics, Nanjing University Medical School Affiliated Jinling Hospital
  • Deputy Secretary, Nanjing University Medical School Affiliated Jinling Hospital
  • Chief Physician, Nanjing University Medical School Affiliated Jinling Hospital
  • Professor, Nanjing University Medical School Affiliated Jinling Hospital
  • Doctoral Supervisor, Nanjing University Medical School Affiliated Jinling Hospital
  • Chinese Orthopedic Physician Association 'Advanced Worker'
  • Second Prize of Military Scientific and Technological Progress
  • Third Prize of Jiangsu Province Scientific and Technological Progress
  • Liu Zhihong Youth Medical Award
  • Third-Class Merit
Clinical and Basic Research of Malignant Bone and Soft Tissue Tumors
  • Circular RNA circFIRRE drives osteosarcoma progression and metastasis through tumorigenic-angiogenic coupling, Lingfeng Yu, Hao Zhu, Zhen Wang, Yan Zhu, Gentao Fan, Yichun Wang, Xi Chen, Guangxin Zhou, 2022
  • In vivo self-assembly and delivery of VEGFR2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy, Yu L, Fan G, Wang Q, Zhu Y, Zhu H, Chang J, Wang Z, Zhan S, Hua X, She D, Huang J, Wang Y, Zhao J, Zhang CY, Chen X, Zhou G, 2023
  • PLOD2 high expression associates with immune infiltration and facilitates cancer progression in osteosarcoma, Wang Z, Fan G, Zhu H, Yu L, She D, Wei Y, Huang J, Li T, Zhan S, Zhou S, Zhu Y, Wang Y, Chen X, Zhao J, Zhou G, 2022
  • Covalent immobilization of VEGF on allogeneic bone through polydopamine coating to improve bone regeneration, Huang J, Lu J, Liu Z, Jin J, Xie C, Zheng Y, Wang Z, Yu L, Zhu Y, Fan G, Sun G, Xu Z, Zhou G, 2022
  • Effect of Angiogenesis in Bone Tissue Engineering, Huang J, Han Q, Cai M, Zhu J, Li L, Yu L, Wang Z, Fan G, Zhu Y, Lu J, Zhou G, 2022
  • Identification of RALA as a Therapeutic Target and Prognostic Predictor of Osteosarcoma, Fan G, Zhu Y, Zhu H, Yu L, Wang Z, Zhai C, Zhou G, Zhao J, Wang Y, 2023
  • Efficacy and safety of treating refractory bone and soft tissue sarcoma with anlotinib in different treatment patterns, Meng Cai, Gentao Fan, Guangxin Zhou, 2022
  • MiR-29b suppresses the proliferation and migration of osteosarcoma cells by targeting CDK6, Zhu K, Liu L, Zhang J, Wang Y, Liang H, Fan G, Jiang Z, Zhang CY, Chen X, Zhou G, 2016
  • Genome-wide CRISPR-Cas9 screen identified KLF11 as a druggable suppressor for sarcoma cancer stem cells, Yicun Wang, Jinhui Wu, Hui Chen, Yang Yang, Chengwu Xiao, Xiaoming Yi, Changjie Shi, Ke Zhong, Haowei He, Yaoming Li, Zhenjie Wu, Guangxin Zhou, Qiu Rao, Xiaoxia Wang, Xiaodie Zhou, Gwen Lomberk, Bing Liu, Jianning Zhao, Jingping Ge, Wenquan Zhou, Xiaoyuan Chu, Cheng Chen, Xuhui Zhou, Linhui Wang, Kunliang Guan, Le Qu, 2021
  • Survival outcomes of patients with brain metastasis of osteosarcoma can be improved by aggressive multi-disciplinary interventions including chemotherapy, Yan Zhu, Gentao Fan, Lili Cao, Hao Zhu, Sujia Wu, Jianning Zhao, Guangxin Zhou, 2021
  • Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma, Fan GT, Ling ZH, He ZW, Wu SJ, Zhou GX, 2021
  • Expression profiles of miRNAs in giant cell tumor of bone showed miR-187-5p and miR-1323 can regulate biological functions through inhibiting FRS2, Jin Y, Zhang J, Zhu H, Fan G, Zhou G, 2020
  • Functions of Exogenous RUNX2 in Giant Cell Tumor of Bone In Vitro, Jin YH, Zhang J, Zhu H, Fan GT, Zhou GX, 2020
  • miR-139 inhibits osteosarcoma cell proliferation and invasion by targeting ROCK1, Fan G, He Z, Cao L, Shi X, Wu S, Zhou G, 2019
  • Association between Mediterranean diet adherence and colorectal cancer: a dose-response meta-analysis, Zhong Y, Zhu Y, Li Q, Wang F, Ge X, Zhou G, Miao L, 2020
  • Efficacy Analysis of Separation Surgery Combined with SBRT for Spinal Metastases-A Long-Term Follow-Up Study Based on Patients with Spinal Metastatic Tumor in a Single-Center, Xiaozhou L, Xing Z, Xin S, Chengjun L, Lei Z, Guangxin Z, Sujia W, 2020
  • MicroRNA-150 functions as a tumor suppressor and sensitizes osteosarcoma to doxorubicin-induced apoptosis by targeting RUNX2, Ling Z, Fan G, Yao D, Zhao J, Zhou Y, Feng J, Zhou G, Chen Y, 2020
  • miR-16 promotes the apoptosis of human cancer cells by targeting FEAT, Liang H, Fu Z, Jiang X, Wang N, Wang F, Wang X, Zhang S, Wang Y, Yan X, Guan WX, Zhang CY, Zen K, Zhang Y, Chen X, Zhou G, 2015
  • Identification of circulating microRNAs in serum as noninvasive biomarkers for detecting and monitoring osteosarcoma, Guangxin Zhou, Meng Lu, Jijun Chen, Chengjun Li, Junfeng Zhang, Jiangning Chen, Xin Shi, Sujia Wu, 2015
  • Mechanical and Biological Properties of a Biodegradable Mg-Zn-Ca Porous Alloy, Zhang YQ, Li Y, Liu H, Bai J, Bao NR, Zhang Y, He P, Zhao JN, Tao L, Xue F, Zhou GX, Fan GT, 2018
  • Preparation and antitumor activity of a polymer derivative of metrotrexate, Zhou Guangxin, Chen Xiaoyu, Wu Sujia, Shi Xin, Chen Jiangning, Zhang Junfeng, 2012
  • A microRNA expression signature predicts meningioma recurrence, Zhi, Feng, Zhou Guangxin, Wang, Suinuan, Shi, Yimin, Peng, Ya, Shao, Naiyuan, Guan, Wei, Qu, Hongtao, Zhang, Yi, Wang, Qiang, Yang, Changchun, Wang, Rong, Wu, Sujia, Xia, Xiwei, Yang, Yilin, 2013
  • MicroRNAs in osteosarcoma: from biological players to clinical contributors, Guangxin Zhou, Xin Shi, Junfeng Zhang, Sujia wu, Jianning Zhao, 2013
  • miR-106a-5p inhibits the proliferation and migration of astrocytoma cells and promotes apoptosis by targeting FASTK, Feng Zhi, Guangxin Zhou, Naiyuan Shao, Xiwei Xia, Yimin Shi, Qiang Wang, Yi Zhang, Rong Wang, Lian Xue, Suinuan Wang, Sujia Wu, Ya Peng, Yilin Yang, 2013
Bone Tumors Soft Tissue Tumors Clinical Research Basic Research Malignancy Oncology Orthopedics Tumor Progression Metastasis Therapeutics

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.